Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond)

被引：13

作者：

Bersanelli, Melissa ^{[1
,2
]}

机构：

[1] Univ Hosp Parma, Med Oncol, I-43126 Parma, Italy

[2] Univ Parma, Dept Med & Surg, Parma, Italy

来源：

LANCET ONCOLOGY | 2020年 / 21卷 / 10期

关键词：

D O I：

10.1016/S1470-2045(20)30433-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1255 / 1257

页数：6

共 6 条

[1]

FDA-NIH Biomarker Working Group, 2016, Reasonably Likely Surrogate Endpoint--BEST (Biomarkers, EndpointS

[2] Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update [J].

Hanna, Nasser H. ;

Schneider, Bryan J. ;

Temin, Sarah ;

Baker, Sherman, Jr. ;

Brahmer, Julie ;

Ellis, Peter M. ;

Gaspar, Laurie E. ;

Haddad, Rami Y. ;

Hesketh, Paul J. ;

Jain, Dharamvir ;

Jaiyesimi, Ishmael ;

Johnson, David H. ;

Leighl, Natasha B. ;

Phillips, Tanyanika ;

Riely, Gregory J. ;

Robinson, Andrew G. ;

Rosell, Rafael ;

Schiller, Joan H. ;

Singh, Navneet ;

Spigel, David R. ;

Stabler, Janis O. ;

Tashbar, Joan ;

Masters, Gregory .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) :1608-+

[3] Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study [J].

Marabelle, Aurelien ;

Fakih, Marwan ;

Lopez, Juanita ;

Shah, Manisha ;

Shapira-Frommer, Ronnie ;

Nakagawa, Kazuhiko ;

Chung, Hyun Cheol ;

Kindler, Hedy L. ;

Lopez-Martin, Jose A. ;

Miller, Wilson H., Jr. ;

Italiano, Antoine ;

Kao, Steven ;

Piha-Paul, Sarina A. ;

Delord, Jean-Pierre ;

McWilliams, Robert R. ;

Fabrizio, David A. ;

Aurora-Garg, Deepti ;

Xu, Lei ;

Jin, Fan ;

Norwood, Kevin ;

Bang, Yung-Jue .

LANCET ONCOLOGY, 2020, 21 (10) :1353-1365

[4] A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing [J].

Matter-Walstra, Klazien ;

Schwenkglenks, Matthias ;

Aebi, Stefan ;

Dedes, Konstantin ;

Diebold, Joachim ;

Pietrini, Mario ;

Klingbiel, Dirk ;

von Moos, Roger ;

Gautschi, Oliver .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) :1846-1855

[5] The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors [J].

Nandakumar, Vijayalakshmi ;

Mills, John R. .

CLINICAL CHEMISTRY, 2019, 65 (02) :357-357

[6]

U.S. Food and Drug Administration, 2020, FDA APPR PEMBR AD CH

← 1 →